Since the approval of the first-generation ADC trastuzumab emtansine (T-DM1) for HER2+ breast cancer in 2013, subsequent generations of ADCs have significantly broadened the therapeutic landscape for advanced or metastatic breast, ovarian, urothelial, gastric and colorectal cancers (Table S3).53 Here, ERBB2 is linked to breast carcinoma.